Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 318 entries
Sorted by: Best Match Show Resources per page
Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab.

Investigational new drugs

Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK.
PMID: 25236593
Invest New Drugs. 2015 Feb;33(1):269-70. doi: 10.1007/s10637-014-0162-x.

No abstract available.

Cite
Lee J, Hong YS, Hong JY, et al. Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Invest New Drugs. 2015;33(1):269-70doi: 10.1007/s10637-014-0162-x.
Lee, J., Hong, Y. S., Hong, J. Y., Han, S. W., Kim, T. W., Kang, H. J., Kim, T. Y., Kim, K. P., Kim, S. H., Do, I. G., Kim, K. M., Sohn, I., Park, S. H., Park, J. O., Lim, H. Y., Cho, Y. B., Lee, W. Y., Yun, S. H., Kim, H. C., Park, Y. S., & Kang, W. K. (2015). Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Investigational new drugs, 33(1), 269-70. https://doi.org/10.1007/s10637-014-0162-x
Lee, Jeeyun, et al. "Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab." Investigational new drugs vol. 33,1 (2015): 269-70. doi: https://doi.org/10.1007/s10637-014-0162-x
Lee J, Hong YS, Hong JY, Han SW, Kim TW, Kang HJ, Kim TY, Kim KP, Kim SH, Do IG, Kim KM, Sohn I, Park SH, Park JO, Lim HY, Cho YB, Lee WY, Yun SH, Kim HC, Park YS, Kang WK. Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Invest New Drugs. 2015 Feb;33(1):269-70. doi: 10.1007/s10637-014-0162-x. PMID: 25236593.
Copy Download .nbib Format: NLM
Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma.

Investigational new drugs

Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N.
PMID: 32578153
Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9.

No abstract available.

Cite
Kroschinsky F, Middeke JM, Janz M, et al. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Invest New Drugs. 2021;39(1):285-286doi: 10.1007/s10637-020-00964-9.
Kroschinsky, F., Middeke, J. M., Janz, M., Lenz, G., Witzens-Harig, M., Bouabdallah, R., La Rosée, P., Viardot, A., Salles, G., Kim, S. J., Kim, T. M., Ottmann, O., Chromik, J., Quinson, A. M., von Wangenheim, U., Burkard, U., Berk, A., & Schmitz, N. (2021). Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Investigational new drugs, 39(1), 285-286. https://doi.org/10.1007/s10637-020-00964-9
Kroschinsky, Frank, et al. "Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma." Investigational new drugs vol. 39,1 (2021): 285-286. doi: https://doi.org/10.1007/s10637-020-00964-9
Kroschinsky F, Middeke JM, Janz M, Lenz G, Witzens-Harig M, Bouabdallah R, La Rosée P, Viardot A, Salles G, Kim SJ, Kim TM, Ottmann O, Chromik J, Quinson AM, von Wangenheim U, Burkard U, Berk A, Schmitz N. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma. Invest New Drugs. 2021 Feb;39(1):285-286. doi: 10.1007/s10637-020-00964-9. PMID: 32578153; PMCID: PMC8025277.
Copy Download .nbib Format: NLM
Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial.

Investigational new drugs

Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T.
PMID: 31025237
Invest New Drugs. 2019 Jun;37(3):592-593. doi: 10.1007/s10637-019-00773-9.

The authors would like to note the replacement of Fig. 2b, for which Fig. 2a was placed erringly, with appropriate Fig. 2b.

Cite
Inoue K, Ninomiya J, Saito T, et al. Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019;37(3):592-593doi: 10.1007/s10637-019-00773-9.
Inoue, K., Ninomiya, J., Saito, T., Okubo, K., Nakakuma, T., Yamada, H., Kimizuka, K., Higuchi, T. (2019). Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Investigational new drugs, 37(3), 592-593. https://doi.org/10.1007/s10637-019-00773-9
Inoue, Kenichi, et al. "Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial." Investigational new drugs vol. 37,3 (2019): 592-593. doi: https://doi.org/10.1007/s10637-019-00773-9
Inoue K, Ninomiya J, Saito T, Okubo K, Nakakuma T, Yamada H, Kimizuka K, Higuchi T. Correction to: Eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: a phase II, multicenter, collaborative, open-label, single-arm clinical trial. Invest New Drugs. 2019 Jun;37(3):592-593. doi: 10.1007/s10637-019-00773-9. PMID: 31025237; PMCID: PMC6828019.
Copy Download .nbib Format: NLM
Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.

Investigational new drugs

Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Hoshino T.
PMID: 32783090
Invest New Drugs. 2021 Feb;39(1):269-271. doi: 10.1007/s10637-020-00983-6. Epub 2020 Aug 11.

Although immune checkpoint inhibitors have improved the survival of small cell lung cancer (SCLC) patients, their efficacy in SCLC patients who relapsed after systemic chemotherapy is unclear. This retrospective study aimed to investigate the utility of treatment with atezolizumab...

Cite
Ishii H, Azuma K, Kawahara A, et al. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy. Invest New Drugs. 2020;39(1):269-271doi: 10.1007/s10637-020-00983-6.
Ishii, H., Azuma, K., Kawahara, A., Matsuo, N., Tokito, T., & Hoshino, T. (2021). Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy. Investigational new drugs, 39(1), 269-271. https://doi.org/10.1007/s10637-020-00983-6
Ishii, Hidenobu, et al. "Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy." Investigational new drugs vol. 39,1 (2021): 269-271. doi: https://doi.org/10.1007/s10637-020-00983-6
Ishii H, Azuma K, Kawahara A, Matsuo N, Tokito T, Hoshino T. Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy. Invest New Drugs. 2021 Feb;39(1):269-271. doi: 10.1007/s10637-020-00983-6. Epub 2020 Aug 11. PMID: 32783090.
Copy Download .nbib Format: NLM
Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.

Investigational new drugs

Osaki M, Tachikawa R, Ohira J, Hara S, Tomii K.
PMID: 32651759
Invest New Drugs. 2021 Feb;39(1):251-255. doi: 10.1007/s10637-020-00974-7. Epub 2020 Jul 10.

Immune checkpoint inhibitors can induce immune-related adverse events (irAEs) in different organs. Dermatomyositis is a rare form of systemic irAE. Although dermatomyositis-specific antibodies, especially anti-transcriptional intermediary factor 1-γ (anti-TIF1-γ) antibodies, have been detected in a few cases of immune...

Cite
Osaki M, Tachikawa R, Ohira J, et al. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report. Invest New Drugs. 2020;39(1):251-255doi: 10.1007/s10637-020-00974-7.
Osaki, M., Tachikawa, R., Ohira, J., Hara, S., & Tomii, K. (2021). Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report. Investigational new drugs, 39(1), 251-255. https://doi.org/10.1007/s10637-020-00974-7
Osaki, Megumu, et al. "Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report." Investigational new drugs vol. 39,1 (2021): 251-255. doi: https://doi.org/10.1007/s10637-020-00974-7
Osaki M, Tachikawa R, Ohira J, Hara S, Tomii K. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report. Invest New Drugs. 2021 Feb;39(1):251-255. doi: 10.1007/s10637-020-00974-7. Epub 2020 Jul 10. PMID: 32651759.
Copy Download .nbib Format: NLM
Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors.

Investigational new drugs

Denlinger CS, Keedy VL, Moyo V, MacBeath G, Shapiro GI.
PMID: 34250553
Invest New Drugs. 2021 Dec;39(6):1604-1612. doi: 10.1007/s10637-021-01145-y. Epub 2021 Jul 11.

Background Overactivation of human epidermal growth factor receptor 3 (HER3) triggers multiple intracellular pathways resulting in tumor cell survival. This Phase 1 study assessed the safety, efficacy, and pharmacokinetics (PK) of seribantumab, a fully human anti-HER3 monoclonal antibody. Methods...

Cite
Denlinger CS, Keedy VL, Moyo V, et al. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2021;39(6):1604-1612doi: 10.1007/s10637-021-01145-y.
Denlinger, C. S., Keedy, V. L., Moyo, V., MacBeath, G., & Shapiro, G. I. (2021). Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Investigational new drugs, 39(6), 1604-1612. https://doi.org/10.1007/s10637-021-01145-y
Denlinger, Crystal S, et al. "Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors." Investigational new drugs vol. 39,6 (2021): 1604-1612. doi: https://doi.org/10.1007/s10637-021-01145-y
Denlinger CS, Keedy VL, Moyo V, MacBeath G, Shapiro GI. Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2021 Dec;39(6):1604-1612. doi: 10.1007/s10637-021-01145-y. Epub 2021 Jul 11. PMID: 34250553; PMCID: PMC8541959.
Copy Download .nbib Format: NLM
IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis.

Investigational new drugs

Lv X, Zhao Q, Dong Y, Yang L, Gong J, Zheng Y, Yang T.
PMID: 35020067
Invest New Drugs. 2022 Jan 12; doi: 10.1007/s10637-021-01210-6. Epub 2022 Jan 12.

Background Hepatocellular carcinoma (HCC) is one of the most common cancers with a high mortality rate due to metastasis and relapse. Purpose Here, we reported a small-molecule pyridazinone compound, designated as IMB5036. Its antitumor activity against HCC and underlying...

Cite
Lv X, Zhao Q, Dong Y, et al. IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis. Invest New Drugs. 2022;doi: 10.1007/s10637-021-01210-6.
Lv, X., Zhao, Q., Dong, Y., Yang, L., Gong, J., Zheng, Y., & Yang, T. (2022). IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis. Investigational new drugs, . https://doi.org/10.1007/s10637-021-01210-6
Lv, Xing, et al. "IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis." Investigational new drugs vol. (2022). doi: https://doi.org/10.1007/s10637-021-01210-6
Lv X, Zhao Q, Dong Y, Yang L, Gong J, Zheng Y, Yang T. IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis. Invest New Drugs. 2022 Jan 12; doi: 10.1007/s10637-021-01210-6. Epub 2022 Jan 12. PMID: 35020067.
Copy Download .nbib Format: NLM
A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Investigational new drugs

Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D, Brown JR.
PMID: 33683501
Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 08.

BI 836826 is a chimeric immunoglobulin G1 antibody targeting CD37, a transmembrane protein expressed on normal and malignant B cells. This open-label, phase Ib, dose-escalation study was conducted to determine the recommended phase II dose (RP2D) of BI 836826...

Cite
Danilov AV, Spurgeon SE, Siddiqi T, et al. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021;39(4):1099-1105doi: 10.1007/s10637-020-01056-4.
Danilov, A. V., Spurgeon, S. E., Siddiqi, T., Quinson, A. M., Maier, D., Smith, D., & Brown, J. R. (2021). A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Investigational new drugs, 39(4), 1099-1105. https://doi.org/10.1007/s10637-020-01056-4
Danilov, Alexey V, et al. "A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia." Investigational new drugs vol. 39,4 (2021): 1099-1105. doi: https://doi.org/10.1007/s10637-020-01056-4
Danilov AV, Spurgeon SE, Siddiqi T, Quinson AM, Maier D, Smith D, Brown JR. A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. Invest New Drugs. 2021 Aug;39(4):1099-1105. doi: 10.1007/s10637-020-01056-4. Epub 2021 Mar 08. PMID: 33683501; PMCID: PMC8279974.
Copy Download .nbib Format: NLM
Network pharmacology of triptolide in cancer cells: implications for transcription factor binding.

Investigational new drugs

Seo EJ, Dawood M, Hult AK, Olsson ML, Efferth T.
PMID: 34213719
Invest New Drugs. 2021 Dec;39(6):1523-1537. doi: 10.1007/s10637-021-01137-y. Epub 2021 Jul 02.

Background Triptolide is an active natural product, which inhibits cell proliferation, induces cell apoptosis, suppresses tumor metastasis and improves the effect of other therapeutic treatments in several cancer cell lines by affecting multiple molecules and signaling pathways, such as...

Cite
Seo EJ, Dawood M, Hult AK, et al. Network pharmacology of triptolide in cancer cells: implications for transcription factor binding. Invest New Drugs. 2021;39(6):1523-1537doi: 10.1007/s10637-021-01137-y.
Seo, E. J., Dawood, M., Hult, A. K., Olsson, M. L., & Efferth, T. (2021). Network pharmacology of triptolide in cancer cells: implications for transcription factor binding. Investigational new drugs, 39(6), 1523-1537. https://doi.org/10.1007/s10637-021-01137-y
Seo, Ean-Jeong, et al. "Network pharmacology of triptolide in cancer cells: implications for transcription factor binding." Investigational new drugs vol. 39,6 (2021): 1523-1537. doi: https://doi.org/10.1007/s10637-021-01137-y
Seo EJ, Dawood M, Hult AK, Olsson ML, Efferth T. Network pharmacology of triptolide in cancer cells: implications for transcription factor binding. Invest New Drugs. 2021 Dec;39(6):1523-1537. doi: 10.1007/s10637-021-01137-y. Epub 2021 Jul 02. PMID: 34213719; PMCID: PMC8541937.
Copy Download .nbib Format: NLM
Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment.

Investigational new drugs

Delbart DI, Giri GF, Cammarata A, Pan MD, Bareño LA, Amigo NL, Bechis A, Suarez AG, Spanevello RÁ, Villaverde MS, Todaro LB, Urtreger AJ.
PMID: 34843006
Invest New Drugs. 2021 Nov 29; doi: 10.1007/s10637-021-01200-8. Epub 2021 Nov 29.

No abstract available.

Cite
Delbart DI, Giri GF, Cammarata A, et al. Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment. Invest New Drugs. 2021;doi: 10.1007/s10637-021-01200-8.
Delbart, D. I., Giri, G. F., Cammarata, A., Pan, M. D., Bareño, L. A., Amigo, N. L., Bechis, A., Suarez, A. G., Spanevello, R. �. �., Villaverde, M. S., Todaro, L. B., & Urtreger, A. J. (2021). Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment. Investigational new drugs, . https://doi.org/10.1007/s10637-021-01200-8
Delbart, Damian Ignacio, et al. "Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment." Investigational new drugs vol. (2021). doi: https://doi.org/10.1007/s10637-021-01200-8
Delbart DI, Giri GF, Cammarata A, Pan MD, Bareño LA, Amigo NL, Bechis A, Suarez AG, Spanevello RÁ, Villaverde MS, Todaro LB, Urtreger AJ. Author Correction: Antineoplastic activity of products derived from cellulose‑containing materials: levoglucosenone and structurally‑related derivatives as new alternatives for breast cancer treatment. Invest New Drugs. 2021 Nov 29; doi: 10.1007/s10637-021-01200-8. Epub 2021 Nov 29. PMID: 34843006.
Copy Download .nbib Format: NLM
Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model.

Investigational new drugs

Kashiwagi H, Kawabata S, Yoshimura K, Fukuo Y, Kanemitsu T, Takeuchi K, Hiramatsu R, Nishimura K, Kawai K, Takata T, Tanaka H, Watanabe T, Suzuki M, Miyatake SI, Nakamura H, Wanibuchi M.
PMID: 34816337
Invest New Drugs. 2021 Nov 24; doi: 10.1007/s10637-021-01201-7. Epub 2021 Nov 24.

Introduction Boron neutron capture therapy (BNCT) is a biologically targeted, cell-selective particle irradiation therapy that utilizes the nuclear capture reaction of boron and neutron. Recently, accelerator neutron generators have been used in clinical settings, and expectations for developing new...

Cite
Kashiwagi H, Kawabata S, Yoshimura K, et al. Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model. Invest New Drugs. 2021;doi: 10.1007/s10637-021-01201-7.
Kashiwagi, H., Kawabata, S., Yoshimura, K., Fukuo, Y., Kanemitsu, T., Takeuchi, K., Hiramatsu, R., Nishimura, K., Kawai, K., Takata, T., Tanaka, H., Watanabe, T., Suzuki, M., Miyatake, S. I., Nakamura, H., & Wanibuchi, M. (2021). Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model. Investigational new drugs, . https://doi.org/10.1007/s10637-021-01201-7
Kashiwagi, Hideki, et al. "Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model." Investigational new drugs vol. (2021). doi: https://doi.org/10.1007/s10637-021-01201-7
Kashiwagi H, Kawabata S, Yoshimura K, Fukuo Y, Kanemitsu T, Takeuchi K, Hiramatsu R, Nishimura K, Kawai K, Takata T, Tanaka H, Watanabe T, Suzuki M, Miyatake SI, Nakamura H, Wanibuchi M. Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model. Invest New Drugs. 2021 Nov 24; doi: 10.1007/s10637-021-01201-7. Epub 2021 Nov 24. PMID: 34816337.
Copy Download .nbib Format: NLM
Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.

Investigational new drugs

Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T.
PMID: 34259953
Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14.

Objectives In EGFR-mutated non-small cell lung cancer (NSCLC) patients, approximately 80-90% of leptomeningeal metastasis (LM) develops after failed initial treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (EGFR-TKI). However, the efficacy of rechallenging with previously administered EGFR-TKIs...

Cite
Miyawaki T, Kenmotsu H, Yabe M, et al. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Invest New Drugs. 2021;39(6):1732-1741doi: 10.1007/s10637-021-01140-3.
Miyawaki, T., Kenmotsu, H., Yabe, M., Kodama, H., Nishioka, N., Miyawaki, E., Mamesaya, N., Kobayashi, H., Omori, S., Wakuda, K., Ono, A., Deguchi, S., Mitsuya, K., Naito, T., Murakami, H., Mori, K., Harada, H., Hayashi, N., Takahashi, K., & Takahashi, T. (2021). Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Investigational new drugs, 39(6), 1732-1741. https://doi.org/10.1007/s10637-021-01140-3
Miyawaki, Taichi, et al. "Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis." Investigational new drugs vol. 39,6 (2021): 1732-1741. doi: https://doi.org/10.1007/s10637-021-01140-3
Miyawaki T, Kenmotsu H, Yabe M, Kodama H, Nishioka N, Miyawaki E, Mamesaya N, Kobayashi H, Omori S, Wakuda K, Ono A, Deguchi S, Mitsuya K, Naito T, Murakami H, Mori K, Harada H, Hayashi N, Takahashi K, Takahashi T. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Invest New Drugs. 2021 Dec;39(6):1732-1741. doi: 10.1007/s10637-021-01140-3. Epub 2021 Jul 14. PMID: 34259953.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 318 entries